Sandbox Reserved 687
From Proteopedia
(Difference between revisions)
Line 4: | Line 4: | ||
== '''Complera: Emtricitabine/rilpivirine/tenofovir''' == | == '''Complera: Emtricitabine/rilpivirine/tenofovir''' == | ||
+ | |||
+ | * Marketed by: Gilead Sciences and Janssen Therapeutics | ||
+ | * Major Indication: [[HIV]] infection | ||
+ | * Drug Class: Combination of nucleoside/tide [[reverse transcriptase]] inhibitor and nonnucleoside [[reverse transcriptase]] inhibitor | ||
+ | * Date of FDA Approval: August 2011 | ||
+ | |||
+ | |||
Revision as of 20:43, 2 May 2013
This Sandbox is Reserved from 30/01/2013, through 30/12/2013 for use in the course "Biochemistry II" taught by Hannah Tims at the Messiah College. This reservation includes Sandbox Reserved 686 through Sandbox Reserved 700. |
To get started:
More help: Help:Editing |
Complera: Emtricitabine/rilpivirine/tenofovir
- Marketed by: Gilead Sciences and Janssen Therapeutics
- Major Indication: HIV infection
- Drug Class: Combination of nucleoside/tide reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor
- Date of FDA Approval: August 2011
Rilpivirine (RPV)
|
RPV in the In red are the binding pocket residues p66 (Leu-100, Lys-101, Lys-103, Val-106, Thr-107, Val-108, Val-179, Tyr-181, Tyr-188, Val-189, Gly-190, Phe-227, Trp-229, Leu- 234, and Tyr-318) and p51(Glu-138). Singh et al.
|
Reverse Transcriptase:
Emtricitabine Image:Emtricitabine3.png
|